INTELLIA THERAPEUTICS Business Summary

Intellia Therapeutics Inc. (NTLA) is a leading clinical-stage biotechnology company specializing in CRISPR/Cas9-based genome editing. The company generates revenue primarily through strategic collaboration and licensing agreements with pharmaceutical giants such as Regeneron and Novartis, which provide upfront payments, research funding, and milestone-based incentives. Its business is bifurcated into two primary segments: in vivo programs, which utilize systemic intravenous delivery to edit disease-causing genes directly within the human body (notably nexiguran ziclumeran or nex-z for ATTR amyloidosis and lonvo-z for hereditary angioedema), and ex vivo programs, which focus on engineering cells outside the body to treat oncological and autoimmune diseases. Intellia operates in a high-stakes competitive landscape alongside CRISPR Therapeutics, Beam Therapeutics, and Editas Medicine, distinguishing itself as a pioneer in systemic in vivo CRISPR delivery with multiple assets currently in late-stage Phase 3 clinical trials. The company was established by a prestigious founding team that includes Nobel laureate Jennifer Doudna, Ph.D., alongside industry and academic leaders Rachel Haurwitz, Rodolphe Barrangou, Erik Sontheimer, Luciano Marraffini, and Derrick Rossi. Leadership is currently spearheaded by President and CEO Dr. John M. Leonard, M.D., who brings over 30 years of R&D experience, including a former tenure as Chief Scientific Officer at AbbVie. Supporting the executive suite are Eliana Clark, Ph.D., as Executive Vice President and Chief Technology Officer (formerly of Biogen), and Birgit Schultes, Ph.D., as Chief Scientific Officer. The company maintains a robust institutional profile with significant backing from ARK Investment Management and Regeneron Pharmaceuticals, while its Board of Directors is chaired by Dr. Frank Verwiel, an industry veteran with extensive strategic experience in the biopharmaceutical sector.